Anchorage Rheumatology Billing Fraud: Full Injections on the Bill, Less in the Syringe

In the Anchorage rheumatology billing fraud case, a physician and her office-manager husband agreed to pay $1,855,144 to settle civil False Claims Act claims arising from drug billing and invented visit time. Their separate criminal guilty pleas admitted the healthcare fraud. For someone who handled the medication, treatment records or claims, the case turns on familiar ground: what the clinic bought, what patients received and what insurers paid for.

The Justice Department announced the pleas and civil agreement on November 18, 2025. In her criminal plea agreement, the physician admitted using free samples, substituted medication and doses smaller than those billed, alongside billing for office services never provided. Federal and commercial insurance plans paid claims arising from the scheme. The Defense Criminal Investigative Service, the FBI and the Food and Drug Administration’s Office of Criminal Investigations were among the agencies that investigated.

The Physician Treated Patients, the Office Manager Built the Claims

The physician’s criminal plea agreement identifies her as the Anchorage clinic’s sole physician and owner. She practiced rheumatology, treating autoimmune and musculoskeletal conditions, including rheumatoid arthritis and psoriatic arthritis, with injectable medications. Her husband performed office and management work.

The plea makes their respective conduct concrete. The physician admitted misrepresenting the identity and quantity of medication she injected and making false entries in medical records. Her account states that the office manager knew the injections and records did not match what patients were told, ordered insufficient medication, and created and submitted fraudulent insurance claims.

The physician’s plea also describes false purchasing figures outside the patient charts. The office manager gave the tax preparer spreadsheets that overstated medical-supply costs even though the couple knew the clinic had not bought the medications it billed for. Those spreadsheets carried the fiction into the clinic’s tax returns.

The Medication on the Claim Was Not the Medication in the Syringe

The physician admitted routinely underdosing patients while the clinic billed as though it had provided a full and proper injection. Her plea also describes injections of free samples, different medication and expired medication. Some stock had been purchased by other patients for their own injections at home.

The deception reached into the examination room. In her plea, the physician admitted hiding needles beneath a clipboard or behind her back so patients would not recognize that the medication differed from what she claimed. She also falsely told patients that they needed injections at the clinic and recorded false information about the substances and quantities administered. We see the absurdity in the paperwork: the chart supplied the treatment story that the physician was concealing from the patient sitting in front of her.

For the period from 2009 through 2024, the plea states that the clinic billed for 4,829 medication units across the drugs while purchasing only 369. Full bills, a fraction of the stock.

The drugs named in the plea included Stelara, Humira, Enbrel and Cimzia. For Stelara, the couple received an average of approximately $12,121 per unit billed to the health care benefit programs.

That is where the ordinary buy-and-bill workflow matters. A practice acquires medication, holds inventory, administers it and bills for the covered drug and administration service. The drug’s billing unit has to match the dose and product represented on the claim. Purchase records, no-cost deliveries, vial inventory, administration records and discarded quantities each describe a different part of that transaction.

A related mismatch appeared in Ophthalmic Consultants, where the Justice Department alleged that the practice used single-use eye-drug vials across multiple patients while billing Medicare, TRICARE and the Federal Employees Health Benefits Program for more medication than it purchased. The common question is how the quantity acquired became the quantity billed. The Anchorage plea adds the physician’s admission that the injection itself could contain a different drug or a smaller dose than promised.

Invented Visit Time Created Another Bill

The same plea describes prolonged office services billed but never provided. The physician admitted making false medical-record statements about how long she treated patients and what treatment she provided. Her account states that the office manager knew those statements were false and that they submitted claims for the invented services.

Time and drug quantity describe different parts of the encounter. An invoice can show which medication arrived, while the chart, schedule and treatment record address what happened during the visit. That makes the actual encounter and the claim for that encounter the useful comparison for an insider who knows the office’s working day.

The plea also describes false drug billing after the couple learned of the government’s criminal investigation. An insider who knows when people learned about an investigation can help explain what they knew when later claims went out.

The Loss and the Civil Settlement

The physician’s criminal plea put the actual health care fraud loss at approximately $12,522,446. Against that loss, the Justice Department’s March 18, 2026 announcement reported that the couple had paid approximately $1.8 million to settle the civil False Claims Act claims.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. For someone with knowledge of false drug or visit claims, we focus on the connection between the treatment, the submitted bill and government money.

What Evidence Does a Whistleblower Need?

For this kind of billing fraud, the useful evidence connects the medication and care actually delivered to the claims sent for payment. We connect what you saw with the records that should agree, from drug purchases to treatment entries and the bill.

The Journal of AHIMA’s 2017 article Busting Bad Medicine: a Call to Action Addressing Healthcare, Fraud, Waste, and Abuse explains why the person behind those records matters. After describing checks of treatment dates, treatment types and signatures, it makes the point plainly:

In this clinic, the physician admitted that the medical records themselves contained false statements. A person who saw the injection, handled the stock or prepared the claim could explain the difference between the chart and the work. We build around that knowledge: what you saw in the practice, how it appeared on the bill and who knew the account had changed.

You Saw What the Clinic Actually Gave

If the drug stock, injections or visit records you handled tell a different story from the claims, speak to one of our Whistleblower Experts about the claims that did not match the care. We work beside you to build your strongest case around that difference and bring in physician billing fraud whistleblower lawyers who understand drug quantities, treatment records and false time claims. We stay beside you from the first conversation through the pursuit of the government’s recovery.